Top Injectable Manufacturer in Suriname – Reliable Pharmaceutical Solutions
Last Updated: September 13, 2026
TL;DR: Suriname has no standalone medicines agency. Marketing authorisation is granted by the Registratiecommissie der geneesmiddelen, which the Ministry of Health calls a working organ of the Ministry of Health, under an Ordinance of 8 May 1896 that is still operative as amended. Its fast track names eleven countries and four further categories, and India is not among them. The full dossier route stays open — on paper, in Dutch or English, filed by a licensed Surinamese importer.
Key Takeaways
There is no standalone drug agency. Authorisations come from the Registratiecommissie der geneesmiddelen, which the Ministry of Health calls a working organ of the Ministry of Health and whose own Code of Conduct describes it as a sub-commission of a Medicines Commission.
The fast-track letter of 16 August 2022 names eleven countries and four further categories — fifteen numbered items. India is not among them, and we found no source placing CDSCO on the PIC/S members list, so that category does not reach India either.
Instruction DVG 189/'25 of 19 February 2025 reserves a power to require an independent, GLP-compliant laboratory report applying to every batch, where the manufacturer has not registered or marketed the product in a country the instruction calls highly regulated.
Registration is not permission to import. A separate import licence comes from the Ministry of Economic Affairs and is approved by the Pharmaceutical Inspectorate, and we found no published route for a foreign manufacturer to file in its own name.
Introduction: What an Injectable Manufacturer in Suriname Has to Prove
Every market in this series opens with the same question — does the country name the foreign regulators whose decisions it will lean on, and is India's CDSCO among them? Suriname names eleven of them. A letter from the Registration Commission to importers, reference 019/2022 and dated Paramaribo, 16 August 2022, lists the Netherlands, England, Germany, Canada, USA, Belgium, France, Switzerland, Norway, Denmark and Sweden, and then four further categories. India is not among them, and we found no source placing CDSCO on the PIC/S members list either.
That is a narrower finding than it sounds. Products from all other countries are expressly provided for, and the route they take is open. The Commission's own Code of Conduct says it assesses on the principle of reliance, so being off the reliance list means a heavier file and a slower lane rather than a closed door. Two of the four further categories — WHO prequalification, and a Caribbean Regulatory System recommendation — name no country at all and stay available product by product.
What Sets a World-Class Injectable Manufacturer in Suriname Apart
The first thing to get right is who the regulator is, because most secondary write-ups get it wrong. Suriname has no standalone medicines agency. Marketing authorisations are granted by the Registratiecommissie der geneesmiddelen, described by the Ministry of Health as a working organ of the Ministry of Health and by its own Code of Conduct as a sub-commission of a Medicines Commission, with at most seven expert members appointed by the President of the Republic. Its legal basis is the Ordinance of 8 May 1896 regulating the practice of pharmacy, operative text G.B. 1960 no. 77, amended several times since — amended, not repealed.
The second is that the dossier is not the one you already have. The regulator calls its annex scheme the Common Technical Dossier, Appendices A to K — one word away from ICH's Common Technical Document, and not the same thing. It is an eleven-item Surinamese list running from quantitative composition of the actives to a statement from the competent authority in the country of production, and it asks along the way for data under tropical conditions and for labels and packaging material in six-fold. We found no published statement that an ICH CTD, ACTD or eCTD dossier is accepted in its place.
Quality Systems Behind Every Sterile Injectable We Ship to Suriname
Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic process simulation, environmental monitoring and container-closure integrity testing. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised vials. Stability follows ICH Q1A with Q1B photostability. Dossiers are built in CTD structure with ACTD available — here they are the raw material for the A to K annexes rather than the filing itself, and the full route wants the WHO-GMP certificate of the API manufacturer as well as of the finished-product site.
Two local details shape the work more than any of that. Both routes require a physical sample with the package leaflet enclosed, showing the country-of-origin registration number; the full route adds a certificate of analysis of that sample, and Annex J asks for samples of the finished dosage form and of the active ingredients in sufficient supply for analysis. For a short-dated parenteral that is a logistics exercise, and the regulator states that for now it is not possible to submit a registration file electronically. On cold chain we found no published Surinamese distribution or temperature guideline, and therefore claim none.
Working out whether Suriname is reachable for your product? Talk to our regulatory team
Why Farbe Firma is the Trusted Injectable Manufacturer in Suriname for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Suriname we can build the A to K annex set, supply the CPP and the WHO-GMP certificates of both the finished-product and the API sites, and generate the stability, release and sample data the file needs. What we cannot do is lodge it. The instructions are addressed to importers, the submitting party must hold a wholesale distribution authorisation and be registered with the Pharmaceutical Inspection Department as an importer, and the cover letter must be signed by the importer's director and by the consultant pharmacist. We hold no Surinamese registration and recommend no partner we have not verified.
The bilateral relationship is unusually warm, and it is routinely oversold. Diplomatic relations date from 1976, the Government of India's own embassy in Paramaribo puts the Indian-origin community at over 27% of the population, more than 550 ITEC training slots have been used, and lines of credit run cumulatively to the tune of US$60 million. On 4 June 2023 the Indian Pharmacopoeia Commission and Suriname's Ministry of Health signed a Pharmacopoeia MoU under which, in the IPC's own words, IP is accepted as a book of standards for medicines in the Republic of Suriname. That is standards recognition, not regulatory reliance. It did not place India on the 2022 fast-track list, which we found unamended, and it waives none of the CPP, the two GMP certificates, the annexes or the sample certificate of analysis.
The numbers are small, and the honest version of them is worth more than a round one. India's embassy puts the population at about 620,000 while UN-based projections carried by population trackers put it nearer 645,000 for 2026, and we report both because they disagree. State supply runs through BGVS, the state medicines company established on 4 February 1983 and described on its own site as the country's largest importer and wholesaler of medicines; SZF, the social health insurer, publishes 271 medicines and consumables on which no patient co-payment may be charged. Our own approximate and partial count of the national medicines list, taken from its own export and covering entries from Abacavir to Doxycycline only, found about 202 product entries of which about 62 are injectable dosage forms — roughly three in ten.
Explore Farbe Firma: Products / Global Reach / About Us
Frequently Asked Questions (FAQ)
Does Suriname recognise India's CDSCO or Indian regulatory approval?
Not on the fast track. The Registration Commission's letter to importers names eleven countries — Netherlands, England, Germany, Canada, USA, Belgium, France, Switzerland, Norway, Denmark and Sweden — plus four further categories, and India is not among them; we also found no source placing CDSCO on the PIC/S members list. An Indian-made product can still reach the fast track product by product, through WHO prequalification or through a CARPHA Caribbean Regulatory System recommendation.
Is the Indian Pharmacopoeia accepted in Suriname?
Yes, as a book of standards. The Pharmacopoeia MoU signed on 4 June 2023 means, in the Indian Pharmacopoeia Commission's own words, that IP is accepted as a book of standards for medicines in the Republic of Suriname. Keep it in proportion: that is compendial recognition, useful in the composition and testing sections of a dossier. It is not regulatory reliance on CDSCO, and we found nothing designating CDSCO as a reference authority for Suriname.
Can we submit a Suriname dossier in ICH CTD format?
The regulator's published scheme is its own eleven-item annex list, which it calls the Common Technical Dossier, Appendices A to K — confusingly close to the ICH Common Technical Document, and not the same thing. We found no published statement that an ICH CTD, ACTD or eCTD dossier is accepted in its place, so plan for A to K. The regulator also states that for now it is not possible to submit a registration file electronically, so filings are hard copy.
Will Suriname require independent batch testing of our injectables?
It may. Ministry of Health instruction DVG 189/'25, dated 19 February 2025, reserves the power — where the manufacturer has not registered or marketed the product in a country the instruction calls highly regulated — to require an analysis report from an independent, GLP-compliant laboratory approved by the regulator of the country of manufacture, applying to every batch for which registration is sought. It defines highly regulated by PIC/S membership, WHO prequalification and WHO Listed Authorities, and allows a waiver on risk assessment. It is a reserved power exercised case by case, not a blanket rule.
Can we register in Suriname without a local partner?
The instructions are addressed to importers and state that the submitting party must have a wholesale distribution authorisation and be registered with the Pharmaceutical Inspection Department of the Ministry of Health as an importer of medicinal products, with the cover letter signed by the importer's director and by the consultant pharmacist. We found no published route for a foreign manufacturer to file in its own name. Separately, a registered product still needs an import licence from the Ministry of Economic Affairs, approved by the Pharmaceutical Inspectorate.
Technically Reviewed By: Maulik Sudani & Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote / View Products / FAQ / Blog
Comments